Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 15,900 shares, a drop of 34.6% from the December 15th total of 24,300 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 38,300 shares, the days-to-cover ratio is presently 0.4 days.

Valneva Price Performance

Shares of VALN traded down $0.09 during mid-day trading on Thursday, hitting $4.22. The company’s stock had a trading volume of 854 shares, compared to its average volume of 39,404. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50. The firm has a market capitalization of $342.92 million, a P/E ratio of -32.46 and a beta of 1.93. The firm has a 50-day simple moving average of $4.38 and a 200 day simple moving average of $5.91.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a report on Friday, October 11th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC boosted its holdings in Valneva SE (NASDAQ:VALN) by 33.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.